The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

Figure 3

Mean percent change in biomarkers with apremilast 20 mg BID and apremilast 30 mg BID at Week 40; no patients were receiving placebo at this time point. Wilcoxon signed rank test (two-sided value for testing the median of zero).